In addition to our lead programs in LipoCurc™ for the treatment of cancer and our CorreQT technology for treatment of cardiac arrhythmia, Signpath is also developing LipoCurc™ and the CorreQT technology for use in other indications. We are studying LipoCurc™ for the treatment of diseases which cause cytokine storm, including Sepsis and COVID-19. We are also investigating application of our CorreQT technology for the mitigation of cardiomyopathy associated with chemotherapy.
LipoCurc and Sepsis Treatment
Severe Sepsis strikes more than a million Americans every year, and 15 to 30 percent of those people die. There is currently no cure for sepsis as is evidenced by the fact that it remains the leading cause of hospital deaths in the U.S. Approximately fifty percent of hospital deaths are due to sepsis. More than $27 billion was spent in 2014 treating Sepsis. Lipocurc is a potent immunomodulator, and addresses the body’s dangerous (and often fatal) immune response to sepsis. LipoCurc has shown dramatic efficacy in state of the art sepsis animal models, increasing survival time, and reducing organ damage when compared with current Sepsis standard of care treatment.
LV Rate of Contraction
In animal studies, guinea pigs who were administered chemotherapy showed significantly greater heart function when the chemotherapy was co-administered with Signpath’s CorreQT adjuvant.
CorreQT technology protects the heart from damage caused by chemotherapy
Protecting the Heart from Damage During Chemotherapy
Using the CorreQT technology platform, Signpath is developing a drug which protects the heart from damage caused by administration of chemotherapy agents. Pre-clinical data shows that Signpath compounds are effective in mitigating the heart muscle damage which is a common side effect of cancer chemotherapy. In addition, testing confirms that Signpath’s compound does not interfere with the anti-cancer efficacy of the chemotherapy agent. Signpath is working on compound optimization for this cancer supportive care indication. The goal is to create a cardio-protective agent that is widely used in conjunction with a broad spectrum of chemotherapy agents (a cancer adjuvant model similar to Amgen’s Neupogen.) The cancer supportive care drug market was $22.9 billion in 2015.